Aptevo Therapeutics Says Mipletamig For AML Treatment Delivers 100% Remission Rate in Phase 1b/2 Study; Shares Up Pre-Bell

MT Newswires Live

Sep 16, 2025

Aptevo Therapeutics (APVO) said Tuesday that its Mipletamig saw a 100% remission rate in group 3 of its phase 1b/2 study evaluating the drug for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.

The clinical-stage company also said no dose-limiting toxicities or cytokine release syndrome were observed in the study.

The company said it expects to present its current findings at a major medical conference in Q4.

Shares of Aptevo were up 65% in recent Tuesday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2567048829"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2567048829\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2567048829?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-16 21:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2567048829","market":"sg","top_or_hot":-1,"title":"Aptevo Therapeutics Says Mipletamig For AML Treatment Delivers 100% Remission Rate in Phase 1b/2 Study; Shares Up Pre-Bell","media":"MT Newswires Live","content":"<html><body><p> Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (APVO) said Tuesday that its Mipletamig saw a 100% remission rate in group 3 of its phase 1b/2 study evaluating the drug for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.</p><p>The clinical-stage company also said no dose-limiting toxicities or cytokine release syndrome were observed in the study.</p><p>The company said it expects to present its current findings at a major medical conference in Q4.</p><p>Shares of Aptevo were up 65% in recent Tuesday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aptevo Therapeutics Says Mipletamig For AML Treatment Delivers 100% Remission Rate in Phase 1b/2 Study; Shares Up Pre-Bell</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAptevo Therapeutics Says Mipletamig For AML Treatment Delivers 100% Remission Rate in Phase 1b/2 Study; Shares Up Pre-Bell\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-16 21:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Aptevo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (APVO) said Tuesday that its Mipletamig saw a 100% remission rate in group 3 of its phase 1b/2 study evaluating the drug for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.</p><p>The clinical-stage company also said no dose-limiting toxicities or cytokine release syndrome were observed in the study.</p><p>The company said it expects to present its current findings at a major medical conference in Q4.</p><p>Shares of Aptevo were up 65% in recent Tuesday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2567048829","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2567048829","pubTimestamp":1758028907,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Aptevo Therapeutics  said Tuesday that its Mipletamig saw a 100% remission rate in group 3 of its phase 1b/2 study evaluating the drug for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.The clinical-stage company also said no dose-limiting toxicities or cytokine release syndrome were observed in the study.The company said it expects to present its current findings at a major medical conference in Q4.Shares of Aptevo were up 65% in recent Tuesday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","APVO":"Aptevo Therapeutics Inc."},"translate_title":"Aptevo Therapeutics表示，用于AML治疗的Mipletamig在1b/2期研究中提供了100%的缓解率；分享盘前","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"APVO":1.5},"content_text":"Aptevo Therapeutics (APVO) said Tuesday that its Mipletamig saw a 100% remission rate in group 3 of its phase 1b/2 study evaluating the drug for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy.The clinical-stage company also said no dose-limiting toxicities or cytokine release syndrome were observed in the study.The company said it expects to present its current findings at a major medical conference in Q4.Shares of Aptevo were up 65% in recent Tuesday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}